Drug intelligence / Profile preview

Lianhua Jizhi Pian

Development stage: Phase 3
Lead developer: Yiling Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Lianhua Jizhi Pian is an investigational Traditional Chinese Medicine (TCM) developed by Shijiazhuang Yiling Pharmaceutical for the treatment of acute tracheobronchitis. Classified as a Category 1.1 innovative TCM in China, it is specifically indicated for the 'phlegm-heat' syndrome, which presents with symptoms such as cough, yellow sputum, and chest congestion. The drug is part of the 'Lianhua' respiratory product line and is formulated as an oral tablet. It aims to provide therapeutic benefits through anti-inflammatory, antitussive, and expectorant actions. As of 2024, Lianhua Jizhi Pian is in Phase 2 clinical development, following the success of other respiratory products from the same developer like Lianhua Qingwen and Lianhua Qingke.

Brand names: Lianhua Jizhi Pian
Other names: Lianhua Jizhi Tablets连花急支片

Beyond the preview

Go deeper on Lianhua Jizhi Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lianhua Jizhi Pian.